In a report released today, Balaji Prasad from Barclays maintained a Buy rating on Teva Pharmaceutical (TEVA – Research Report), with a price ...

Teva and Sanofi's duvakitug showed promising results in a Phase 2b study for ulcerative colitis and Crohn's disease, with ...

Sound Shore Management, an investment management firm, has released its investor letter for the fourth quarter of 2024. A ...

AXSM stock rises 20% as it settles Auvelity patent litigation with Teva, protecting the drug's exclusivity in the United ...

On February 18, 2025, Teva Pharmaceutical Industries Limited (NYSE:TEVA) stock closed at $16.57 per share with a market capitalization of $19.17 billion. Sound Shore Management stated the ...

Teva Pharmaceutical Industries' Q4 2024 results were strong, but 2025 guidance underwhelmed, causing a sharp stock sell-off. Management's cautious 2025 guidance sets a low bar, likely to be ...

Shares of Teva Pharmaceutical Industries ( TEVA -2.29%) were slipping Wednesday. The company's stock lost 13.5% as of 1:15 p.m. ET. The leg down comes as the S&P 500 ( ^GSPC -0.01%) and Nasdaq ...

Teva Pharmaceuticals (TEVA), and Sanofi (SNY) presented new, detailed results from the RELIEVE UCCD Phase 2b study of duvakitug, a human IgG1-2 ...

Corcept Therapeutics (CORT) stock turned lower after a group of insurers sued the company for blocking Teva's (TEVA) launch of generic Korlym. Read more here.

TEVA PHARMACEUTICAL INDUSTRIES LTD (ADR) (TEVA) is a large-cap growth stock in the Biotechnology & Drugs industry. The rating using this strategy is 78% based on the firm’s underlying ...